Insider Selling: Alkermes PLC (ALKS) Director Sells $2,443,500.00 in Stock

Alkermes PLC (NASDAQ:ALKS) Director Richard F. Pops sold 50,000 shares of the business’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $48.87, for a total transaction of $2,443,500.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Alkermes PLC (NASDAQ ALKS) opened at $50.99 on Monday. The company has a current ratio of 3.05, a quick ratio of 2.72 and a debt-to-equity ratio of 0.23.

Alkermes PLC (NASDAQ:ALKS) last posted its quarterly earnings results on Thursday, October 26th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.04. Alkermes PLC had a negative net margin of 20.12% and a negative return on equity of 7.27%. The firm had revenue of $217.40 million during the quarter, compared to analyst estimates of $231.29 million. During the same quarter in the prior year, the business posted ($0.09) earnings per share. The company’s quarterly revenue was up 20.6% compared to the same quarter last year. equities analysts expect that Alkermes PLC will post -0.59 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This report was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.com-unik.info/2017/11/06/insider-selling-alkermes-plc-alks-director-sells-2443500-00-in-stock.html.

A number of large investors have recently bought and sold shares of ALKS. Toronto Dominion Bank raised its position in Alkermes PLC by 12.7% in the second quarter. Toronto Dominion Bank now owns 1,875 shares of the company’s stock worth $109,000 after purchasing an additional 212 shares in the last quarter. Daiwa SB Investments Ltd. acquired a new position in Alkermes PLC in the second quarter worth about $166,000. Greenwood Capital Associates LLC raised its position in Alkermes PLC by 1.1% in the second quarter. Greenwood Capital Associates LLC now owns 3,770 shares of the company’s stock worth $219,000 after purchasing an additional 41 shares in the last quarter. US Bancorp DE raised its position in Alkermes PLC by 366.4% in the second quarter. US Bancorp DE now owns 3,974 shares of the company’s stock worth $231,000 after purchasing an additional 3,122 shares in the last quarter. Finally, Insight Capital Research & Management Inc. acquired a new position in Alkermes PLC in the second quarter worth about $232,000. 98.19% of the stock is owned by hedge funds and other institutional investors.

A number of research firms have weighed in on ALKS. J P Morgan Chase & Co set a $78.00 target price on shares of Alkermes PLC and gave the stock a “buy” rating in a research report on Friday, October 27th. BidaskClub lowered shares of Alkermes PLC from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 9th. UBS AG set a $54.00 target price on shares of Alkermes PLC and gave the stock a “hold” rating in a research report on Friday, October 27th. Barclays PLC set a $50.00 target price on shares of Alkermes PLC and gave the stock a “hold” rating in a research report on Thursday, October 26th. Finally, Credit Suisse Group cut their target price on shares of Alkermes PLC from $70.00 to $66.00 and set an “outperform” rating for the company in a research report on Friday, October 27th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $63.55.

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Insider Buying and Selling by Quarter for Alkermes PLC (NASDAQ:ALKS)

What are top analysts saying about Alkermes PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alkermes PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit